Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Post-ASCO & EHA 2024 MPN Highlights
25 June 2024 | Virtual Meeting
Presentation summaries of key MPN abstracts from ASCO & EHA 2024 featuring panel discussions with leading experts
The Post-ASCO & EHA 2024 MPN Highlights was supported by GSK. Supporters have no influence over the production of content.
Novel treatments and treatment combinations for MPNs
JAK2V617F molecular response correlates with EFS in an early PV population
Jean-Jacques Kiladjian Saint-Louis Hospital & Paris Diderot University, Paris, France
RESTORE: Elritercept for MF and mitigating ruxolitinib-associated cytopenias
Claire Harrison Guy’s and St. Thomas’ NHS Foundation Trust, London, United Kingdom
MANIFEST-2: pelabresib + ruxolitinib for JAKi treatment-naïve pts with MF
Raajit Rampal Memorial Sloan Kettering Cancer Center, New York City, NY, United States
TRANSFORM-1: navitoclax + RUX vs. RUX + PBO in pts with untreated MF
Naveen Pemmaraju The University of Texas MD Anderson Cancer Center, Houston, TX, United States
A novel CAR-T cell therapy against calreticulin mutant neoplasms
Alex Rampotas University College London Cancer Institute, London, United Kingdom
Session 1 panel discussion
Updates in outcomes following HSCT in myelofibrosis
Comparing pre-tranplant, peri-transplant and no JAKi on outcomes after HSCT for MF
Kristin Rathje University Medical Center Hamburg-Eppendorf, Hamburg, Germany
Hypomethylating agents are effective in treating relapsed MF post allo-HSCT
Haris Ali City of Hope, Duarte, CA, United States
Session 2 panel discussion
Current evidence for long-term & real-world outcomes
Clinical & molecular characterisation of pts w. low JAK2V617F allele burden
Nieves Garcia-Gisbert Hospital del Mar Research Institute, Barcelona, Spain
Momelotinib as an alternative therapy to other JAKi in MF pts with anemia
Valentin Garcia Gutiérrez Ramón y Cajal Hospital, Madrid, Spain
RW treatment patterns & outcomes in pts w. MF treated w. pacritinib in USA
John Mascarenhas Icahn School of Medicine at Mount Sinai, New York City, NY, United States
Session 3 panel discussion
Supported by:
Gold Supporters
